Anavex Life Sciences Corp. (AVXL) | Daily Alert July 21
Anavex continues to move forward with its lead compound Anavex 2-73, currently in clinical trials for Alzheimer’s, Parkinson’s dementia and Rett syndrome. The lead indication, Alzheimer’s, is currently in a 450-patient, 48-week pivotal Phase 2b/3 trial and way more than 50% enrolled.
While enrollment so far has been in Australia, enrollment was recently cleared for sites in the UK and Canada, so I expect some word on results towards the end of 2021. This could be huge as there is nothing out there that really helps Alzheimer’s patients.
While Anavex has some strong data showing a marked slowing, even improvement, in the advancement of Alzheimer’s from a Phase 2 trial, it was equally encouraging to read a quote in a news article by an Alzheimer’s clinician (who therefore knows how Alzheimer’s patients usually progress) who said, “It is so exciting to be part of this trial and seeing what we are seeing in these patients overall.”
Meanwhile preliminary data on its Phase 2 Parkinson’s dementia trial is due around mid-year (so, any time now). And data from a 50% overenrolled Phase 2 Rett trial is due by the end of summer (following encouraging data on improvements in sleep, hand movement and breathing from a readout of the first 6 patients). So, it is an exciting time for Anavex, and investors have been taking notice.
Tom Bishop, BI Research, www.biresearch.com, June 30, 2020